del Nido Cardioplegia Solution, 1000 mL, Single-Dose Container, Rx Only Nephron 503B Outsourcing ...
FDA Drug Recall #D-0151-2020 — Class II — October 9, 2019
Recall Summary
| Recall Number | D-0151-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 9, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center |
| Location | West Columbia, SC |
| Product Type | Drugs |
| Quantity | 1047 bags |
Product Description
del Nido Cardioplegia Solution, 1000 mL, Single-Dose Container, Rx Only Nephron 503B Outsourcing Facility 4500 12th St. Extension West Columbia, SC 29172 NDC: 69374-984-10
Reason for Recall
Lack of Assurance of Sterility; bags have potential to leak
Distribution Pattern
Nationwide.
Lot / Code Information
Lots: NC9048A Exp. 10/14/2019; NC9048B Exp. 10/14/2019; NC9049A Exp. 10/16/2019; NC9049B Exp. 10/16/2019; NC9051A Exp. 10/21/2019; NC9051B Exp. 10/21/2019; NC9052A Exp. 10/22/2019; NC9052B Exp. 10/22/2019; NC9053A Exp. 10/23/2019; NC9053B Exp. 10/23/2019; NC9054A Exp. 10/28/2019; NC9054B Exp. 10/28/2019; NC9055A Exp. 10/30/2019; NC9056B Exp. 11/04/2019
Other Recalls from Nephron Pharmaceuticals Corporation d...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0154-2020 | Class III | PF-Succinylcholine Chloride Injection, USP 20 m... | Oct 21, 2019 |
| D-0150-2020 | Class II | Amino Acid Injection 50 g/1000 mL (50 mg/mL) 25... | Oct 9, 2019 |
| D-0148-2020 | Class II | PF-Fentanyl Citrate 2 mcg/mL* & Bupivacaine HCl... | Oct 9, 2019 |
| D-0147-2020 | Class II | PF-Fentanyl Citrate (2 mcg/mL)* & Bupivacaine H... | Oct 9, 2019 |
| D-0149-2020 | Class II | PF-Fentanyl Citrate 2 mcg/mL* & Ropivacaine HCl... | Oct 9, 2019 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.